Explore

Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer
Trendline Trendline
JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston
Trendline Trendline
Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer

Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer

Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on INBRX-106 Study in Head and Neck Cancer

Inhibrx Announces Webcast for Clinical Update on INBRX-106 Study in Head and Neck Cancer

Inhibrx Announces Webcast for Clinical Update on INBRX-106 Study in Head and Neck Cancer
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy